Clinical Scorecard: Earlier Intervention for Neurotrophic Keratitis?
At a Glance
| Category | Detail |
|---|---|
| Condition | Neurotrophic Keratitis |
| Key Mechanisms | Decellularized basement membrane (DBM) grafts for corneal epithelial resolution and sensitivity improvement. |
| Target Population | Patients with chronic subclinical or Mackie Stage 1 neurotrophic keratitis. |
| Care Setting | Ophthalmology clinics and practices. |
Key Highlights
- Corneal epithelial resolution occurred in all eyes with complete follow-up.
- Functional corneal sensitivity improved significantly in advanced Brill severity groups.
- 70–82% of eyes with abnormal baseline osmolarity normalized after treatment.
- MMP-9 positivity decreased, with 56–66% of positive eyes converting to negative.
- Mean DBM use varied by disease severity, with more grafts used in advanced cases.
Guideline-Based Recommendations
Diagnosis
- Conduct corneal sensitivity testing at patient presentation of symptoms.
Management
- Consider Biovance Ocular decellularized basement membrane products as a first-line approach for NK.
Monitoring & Follow-up
- Evaluate corneal epithelial resolution, sensitivity, tear osmolarity, and MMP-9 status post-treatment.
Risks
- Potential underdiagnosis of neurotrophic keratitis.
Patient & Prescribing Data
Patients with neurotrophic keratitis, particularly those with compromised corneal sensitivity.
DBM grafts may lead to significant improvements in corneal health and sensitivity.
Clinical Best Practices
- Document corneal sensitivity prior to intervention.
- Utilize DBM grafts early in the treatment of neurotrophic keratitis.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
